Paul Sekhri Biography and Net Worth

Director of Veeva Systems

Paul Sekhri has more than 25 years’ experience in life sciences, having served in executive leadership positions at some of the most widely regarded pharmaceutical companies in the world. He is President and CEO of eGenesis, a biotechnology company focused on xenotransplantation. Previously, Paul served as president and CEO of Lycera, an innovative biopharmaceutical company focused on treatments for autoimmune diseases and cancer. Prior to Lycera, he was operating partner at Highline Therapeutics, a biotech incubator launched by Versant Ventures. Paul also served as senior vice president, integrated care at Sanofi where he led the creation of innovative solutions and business models to meet patient needs. Before Sanofi, Paul led global business development and was chief strategy officer at Teva. He also served as operating partner and head, biotech ops
group at TPG Biotech, the life sciences venture arm of the global private investment firm TPG, where he was responsible for a portfolio of more than 50 life sciences companies. He has held the roles of founder, president, and chief executive officer of Cerimon Pharmaceuticals; president and chief business officer of ARIAD Pharmaceuticals; and partner for healthcare investments of New Leaf Ventures. Paul spent four years at Novartis, where he held various senior positions, including senior vice president, head of global search and evaluation, business development and licensing, and global head, early commercial development, where he developed the disease area strategy, and founded the early commercial development department.

Paul has served as a director on more than 24 private and public company boards, including BiomX, Ipsen, Compugen, Alpine Immune Sciences, Pharming N.V., Topas Therapeutics, Petra Pharma Corporation, Enumeral Biomedical Holdings, Inc., KAI Pharmaceuticals, Intercept Pharmaceuticals, Macrogenics, PatientSafe Solutions, Tandem Diabetes, and as board advisor to IMS Health.

Paul completed post-graduate studies in clinical anatomy and neuroscience at the University of Maryland, School of Medicine and received his bachelor of
science degree in zoology from the University of Maryland, College Park.

What is Paul J. Sekhri's net worth?: The estimated net worth of Paul J. Sekhri is at least $3.10 million as of September 11th, 2023. Mr. Sekhri owns 14,484 shares of Veeva Systems stock worth more than $3,103,342 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Sekhri may own. Learn More about Paul J. Sekhri's net worth.
How do I contact Paul J. Sekhri?: The corporate mailing address for Mr. Sekhri and other Veeva Systems executives is 4280 HACIENDA DRIVE, PLEASANTON CA, 94588. Veeva Systems can also be reached via phone at (925) 452-6500 and via email at [email protected]. Learn More on Paul J. Sekhri's contact information.
Has Paul J. Sekhri been buying or selling shares of Veeva Systems?: Paul J. Sekhri has not been actively trading shares of Veeva Systems during the last ninety days. Most recently, Paul J. Sekhri sold 2,500 shares of the business's stock in a transaction on Monday, September 11th. The shares were sold at an average price of $224.85, for a transaction totalling $562,125.00. Following the completion of the sale, the director now directly owns 14,484 shares of the company's stock, valued at $3,256,727.40. Learn More on Paul J. Sekhri's trading history.
Who are Veeva Systems' active insiders?: Veeva Systems' insider roster includes Timothy Barabe (Director), Brent Bowman (CFO), Timothy Cabral (CFO), Paul Chamberlain (Director), Ronald Codd (Director), Jonathan Faddis (SVP), Peter Gassner (Founder, CEO, Director), Mary Hedley (Director), Frederic Lequient (SVP), Alan Mateo (EVP), Michele O'connor (CAO), Thomas Schwenger (COO), Paul Sekhri (Director), Matthew Wallach (President), and Eleni Zuppas (CMO). Learn More on Veeva Systems' active insiders.
Are insiders buying or selling shares of Veeva Systems?: In the last year, insiders at the technology company sold shares 16 times. They sold a total of 81,287 shares worth more than $15,843,847.50. The most recent insider tranaction occured on November, 8th when insider Thomas D Schwenger sold 1,126 shares worth more than $270,251.26. Insiders at Veeva Systems own 10.5% of the company. Learn More about insider trades at Veeva Systems.
Information on this page was last updated on 11/8/2024.

Paul J. Sekhri Insider Trading History at Veeva Systems

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/11/2023	Sell	2,500	$224.85	$562,125.00	14,484
3/3/2023	Sell	2,658	$181.93	$483,569.94	16,381
3/31/2022	Sell	11,000	$214.02	$2,354,220.00
3/27/2020	Sell	1,854	$145.50	$269,757.00	10,295
12/6/2019	Sell	4,615	$146.11	$674,297.65	11,550
10/4/2019	Sell	628	$151.00	$94,828.00	16,165
6/24/2019	Sell	601	$169.38	$101,797.38	16,494
3/22/2019	Sell	600	$127.53	$76,518.00	16,468
12/26/2018	Sell	601	$85.00	$51,085.00	16,440
12/18/2018	Sell	9,029	$86.68	$782,633.72	18,266
12/3/2018	Sell	6,016	$98.09	$590,109.44	31,459
9/24/2018	Sell	601	$103.67	$62,305.67	11,459
6/25/2018	Sell	1,107	$82.80	$91,659.60	11,432
3/23/2018	Sell	1,108	$75.46	$83,609.68	13,046
2/28/2018	Sell	4,622	$65.00	$300,430.00
12/7/2017	Sell	10,971	$53.83	$590,568.93	27,438
10/11/2016	Sell	17,593	$37.73	$663,783.89	21,108

Paul J. Sekhri Buying and Selling Activity at Veeva Systems

Veeva Systems Company Overview

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. The company also provides Veeva Development Cloud, a suite of applications for the clinical, regulatory, quality, and safety functions, including Veeva Vault Clinical, Veeva Vault RIM, Veeva Vault Safety, and Veeva Vault Quality; Veeva QualityOne, a quality and document management, and training solution; Veeva RegulatoryOne, a solution that helps companies to manage regulatory submission content; and Veeva Claims addresses the end-to-end product and marketing claims management process. In addition, it offers professional and support services, including implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; data migration and systems integrations technical consulting services; training on its solutions; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.

Today's Range

Now: $214.26

$209.79

$214.26

50 Day Range

MA: $214.68

$201.83

$237.00

2 Week Range

Now: $214.26

$165.12

$240.68

Volume

207,632 shs

Average Volume

949,851 shs

Market Capitalization

$34.70 billion

P/E Ratio

57.14

Dividend Yield

N/A

Beta

0.81

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.